All In Biotech

Drug Trial Radar · NCT04533581

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Sep 17, 2020

Primary completion

May 31, 2028

Study completion May 31, 2028

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.

Conditions

  • Indolent B-cell Non-Hodgkin's Lymphoma

Interventions

  • ME-401Drug

    In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to approximately 2 years

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Akita University Hospital

    Akita, Japan

  • Aomori Prefectural Central Hospital

    Aomori, Japan

  • Chiba Cancer Center

    Chiba, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • National Hospital Organization Kumamoto Medical Center

    Kumamoto, Japan

  • Japanese Red Cross Kyoto Daini Hospital

    Kyoto, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Anjo Kosei Hospital

    Anjo, Aichi-ken, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • Japanese Red Cross Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • Kameda Medical Center

    Kamogawa, Chiba, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Gunma University Hospital

    Maebashi, Gunma, Japan

  • Chugoku Central Hospital

    Fukuyama, Hiroshima, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Ishikawa Prefectural Central Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Kurashiki Central Hospital

    Kurashiki, Okayama-ken, Japan

  • Kindai University Hospital

    Sayama, Osaka, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, Japan

  • Tokyo Metropolitan Komagome Hospital

    Bunkyo-ku, Tokyo, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-ku, Tokyo, Japan

  • Tottori University Hospital

    Yonago, Tottori, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.